Integra LifeSciences Reports Third Quarter 2018 Financial Results

Go back to Integra LifeSciences Reports Third Quarter 2018 Financial Results

Integra LifeSciences (IART) PT Lowered to $62 at JMP Securities

November 2, 2018 8:15 AM EDT

JMP Securities analyst, David Turkaly, lowered the price target on Integra LifeSciences (NASDAQ: IART) to $62.00 (from $66.00) while maintaining a Market Outperform rating following the company's 3Q report.

IART reported a solid uptick in organic growth in 3Q, which was mathematically... More

Integra LifeSciences (IART) PT Lowered to $58 at RBC Capital

November 1, 2018 6:41 AM EDT

RBC Capital analyst Glenn Novarro lowered the price target on Integra LifeSciences (NASDAQ: IART) to $58.00 (from $60.00) while maintaining a Sector Perform rating.

... More

Integra LifeSciences (IART) Reports In-Line Q3 EPS, Revenues Miss; Raises FY18 Revenue Outlook, Maintains FY18 EPS Guidance

October 31, 2018 6:13 AM EDT

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.59, in-line with the analyst estimate of $0.59. Revenue for the quarter came in at $365.9 million versus the consensus estimate of $370.41 million.

Reported revenue was $365.9 million, an increase of 31.2% compared to the third quarter of 2017 with the acquisition of Codman contributing $78.9 million, and organic revenues increased 6.2% over the third quarter of 2017;GAAP... More